Developer docs
API playgroundTry for free, no card

Search company profiles

Avid Bioservices

Full company profile

uuid0003gps

Namestring
Avid Bioservices
Legal namestring
Avid Bioservices, Inc.
Websiteurl
avidbio.com
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) specializing in mammalian cell-culture-based protein production for biotech and pharmaceutical innovators. Founded in 1993 as a subsidiary of Peregrine Pharmaceuticals and spun out as an independent public company (NASDAQ: CDMO) in 2018, Avid was acquired in February 2025 by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion take-private transaction and now operates as a privately held Delaware-incorporated company headquartered in Tustin, California.

The company's technology platform centers on single-use bioreactor-based mammalian cell-culture manufacturing with over 20,000 liters of installed bioreactor capacity, transposase-based proprietary cell line development methods, integrated process and analytical development, and FDA-compliant CGMP production. Operations run across two purpose-built Southern California facilities: a roughly 160,000 sq. ft. Tustin campus supporting late-stage clinical and commercial manufacturing (including the 2023-commissioned Myford DS Line 3) and a 78,000 sq. ft. Early Phase Center of Excellence in Costa Mesa opened in February 2026 for early clinical programs. Avid cites a 23-year FDA inspection track record, 10 successful pre-approval/pre-license inspections, 600+ CGMP batches produced, 7 approved commercial products, and a footprint spanning products marketed in 90+ countries.

Avid generates revenue on a fee-for-service, contract-manufacturing basis through direct enterprise sales to emerging biotech companies, large pharmaceutical companies, and early-stage biologics programs. Services span the full development-to-commercial continuum — cell line development, process development, analytical services, IND-enabling activities, tech transfer, PPQ campaigns, and commercial drug substance supply — and are project-priced and quote-based. The go-to-market is event- and relationship-driven: heavy presence at BIO International, DCAT Week, BPI West, and the JP Morgan Healthcare Conference, supplemented by technical webinars, white papers, and direct senior-executive engagement with biotech and pharma decision-makers. The company employs 350+ staff and is explicitly expanding headcount and capacity to meet growing customer demand.

Short descriptiontext

Avid Bioservices is a mammalian cell-culture biologics CDMO providing process development, analytical, and CGMP manufacturing services from early-phase through commercial supply, serving emerging biotech and large pharmaceutical clients from facilities in Tustin and Costa Mesa, California.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersTustin, United States
HQ citystring
Tustin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, mammalian cell culture, biopharmaceutical CDMO services, CGMP manufacturing, process development services
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
Product category
Biologics Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Avid generates revenue through fee-for-service contract manufacturing agreements for mammalian cell culture biologics. Services span process development, analytical testing, CGMP manufacturing, and tech transfer. Revenue is project-based with long-term client relationships typically encompassing multiple phases from early development through commercial supply.

avidbio.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end mammalian cell-culture manufacturing services for biopharmaceutical clients. Its offerings span process development, analytical services, CGMP clinical and commercial manufacturing, and quality systems, delivered through two specialized California facilities—a 160,000 sq. ft. Tustin campus for late-stage/commercial production and a 78,000 sq. ft. Costa Mesa Early Phase Center of Excellence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10 successful pre-approval/pre-license inspections
+3 more records
Product overview1 text field

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing mammalian cell-culture manufacturing services. The company offers a unified portfolio centered on Mammalian Protein Development & Manufacturing as its core product, supplemented by two specialized facilities: the Early Phase Center of Excellence in Costa Mesa (78,000 sq. ft.) for early clinical programs and the Clinical & Commercial Manufacturing campus in Tustin (160,000 sq. ft.) for late-stage and commercial production. The service portfolio encompasses four integrated modules—Process Development, CGMP Manufacturing, Analytical Services, and Quality Systems—that collectively enable end-to-end capabilities from concept to commercial supply.

Product and service3 records
1Mammalian Protein Development & Manufacturing
CategoryBiologics CDMO Services
Description

End-to-end CDMO services for mammalian protein production spanning early development through commercial CGMP manufacturing, including process development, analytical services, and quality systems for biotech and pharmaceutical clients.

2Early Phase Center of Excellence
CategoryEarly-Phase Biologics CDMO Services
Description

78,000 square foot purpose-built facility in Costa Mesa, California designed to support early clinical programs with integrated cell line development, process development, analytical development, IND-enabling activities, and early formulation development.

3Clinical & Commercial Manufacturing (Tustin Campus)
CategoryLate-Stage / Commercial Biologics Manufacturing
Description

Approximately 160,000 sq. ft. integrated mammalian protein process development and CGMP manufacturing facility supporting late-stage clinical and commercial biologics production with over 20,000L of installed single-use bioreactor capacity.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1CHO Plus
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-05
Description

CHO Plus partnered with Avid Bioservices as scale-up partner for BARDA's BioMaP Consortium project developing high productivity CHO cell lines for filovirus monoclonal antibody production. Avid provides manufacturing scale-up services to support industrial-scale requirements for the BARDA-funded program worth up to $10.4 million over 30 months.

avidbio.com
Strategic tierCoreTypeOthersAnnounced on2025-08-05
Description

Avid Bioservices serves as scale-up partner within BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), supporting domestic manufacturing capacity for medical countermeasures including filovirus monoclonal antibodies.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Samsung Biologics is one of the world's largest mammalian cell culture CDMOs with massive bioreactor capacity (600,000L+). Direct competitor for commercial-scale biologics manufacturing contracts but operates at materially larger scale than Avid.

TypeBroad incumbent
Description

Lonza's Biologics division is the global #1 CDMO offering mammalian cell culture manufacturing from early development through commercial supply. Closest direct competitor in scale, scope, and service mix; competes with Avid for both early-phase and commercial programs.

TypeBroad incumbent
Description

Fujifilm Diosynth Biotechnologies is a leading global CDMO offering mammalian and microbial biologics manufacturing. Notably, Avid's new CEO Kenneth Bilenberg was previously COO of Fujifilm Biotechnologies, making this a particularly relevant peer relationship.

TypeBroad incumbent
Description

WuXi Biologics is a major global biologics CDMO based in China offering end-to-end mammalian cell culture services. A key direct competitor but increasingly losing US biotech work to Avid and other US-based CDMOs due to BIOSECURE Act and onshoring trends.

TypeDirect peer
Description

AGC Biologics is a pure-play mammalian and microbial biologics CDMO with comparable scale to Avid (~20,000L range). Direct competitor for mid-market biotech and pharma biologics manufacturing programs.

TypeBroad incumbent
Description

Catalent is a major global CDMO (now under Novo Holdings) with biologics manufacturing capabilities among other modalities. Overlaps with Avid in mammalian biologics but operates across a much broader service portfolio.

TypeDirect peer
Description

Rentschler Biopharma is a privately held, Germany-based CDMO specializing in mammalian cell culture biologics manufacturing. Very comparable in scale, service mix, and target market (mid-market biotech) to Avid.

8KBI Biopharma
TypeDirect peer
Description

KBI Biopharma is a US-based CDMO focused on mammalian cell culture biologics development and manufacturing. Direct competitor particularly for early-phase programs; comparable footprint and customer profile.

TypeBroad incumbent
Description

Thermo Fisher's Pharma Services (including the legacy Patheon and Brammer Bio biologics operations) is a major global CDMO offering mammalian biologics manufacturing. Broad incumbent competing for late-stage and commercial programs at scale.

TypeEmerging player
Description

Bionova Scientific is a US-based biologics CDMO focused on mammalian cell culture development and GMP manufacturing for early-phase programs. Emerging peer with similar focus area to Avid's Early Phase Center of Excellence.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avid Bioservices

Biologics Contract Manufacturing (CDMO)avidbio.com

Avid Bioservices is a mammalian cell-culture biologics CDMO providing process development, analytical, and CGMP manufacturing services from early-phase through commercial supply, serving emerging biotech and large pharmaceutical clients from facilities in Tustin and Costa Mesa, California.

What Avid Bioservices does

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) specializing in mammalian cell-culture-based protein production for biotech and pharmaceutical innovators. Founded in 1993 as a subsidiary of Peregrine Pharmaceuticals and spun out as an independent public company (NASDAQ: CDMO) in 2018, Avid was acquired in February 2025 by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion take-private transaction and now operates as a privately held Delaware-incorporated company headquartered in Tustin, California.

The company's technology platform centers on single-use bioreactor-based mammalian cell-culture manufacturing with over 20,000 liters of installed bioreactor capacity, transposase-based proprietary cell line development methods, integrated process and analytical development, and FDA-compliant CGMP production. Operations run across two purpose-built Southern California facilities: a roughly 160,000 sq. ft. Tustin campus supporting late-stage clinical and commercial manufacturing (including the 2023-commissioned Myford DS Line 3) and a 78,000 sq. ft. Early Phase Center of Excellence in Costa Mesa opened in February 2026 for early clinical programs. Avid cites a 23-year FDA inspection track record, 10 successful pre-approval/pre-license inspections, 600+ CGMP batches produced, 7 approved commercial products, and a footprint spanning products marketed in 90+ countries.

Avid generates revenue on a fee-for-service, contract-manufacturing basis through direct enterprise sales to emerging biotech companies, large pharmaceutical companies, and early-stage biologics programs. Services span the full development-to-commercial continuum — cell line development, process development, analytical services, IND-enabling activities, tech transfer, PPQ campaigns, and commercial drug substance supply — and are project-priced and quote-based. The go-to-market is event- and relationship-driven: heavy presence at BIO International, DCAT Week, BPI West, and the JP Morgan Healthcare Conference, supplemented by technical webinars, white papers, and direct senior-executive engagement with biotech and pharma decision-makers. The company employs 350+ staff and is explicitly expanding headcount and capacity to meet growing customer demand.

Avid Bioservices firmographics

Firmographics
Name
Avid Bioservices
Legal name
Avid Bioservices, Inc.
Website
https://avidbio.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
251–500 employees
Short description
Avid Bioservices is a mammalian cell-culture biologics CDMO providing process development, analytical, and CGMP manufacturing services from early-phase through commercial supply, serving emerging biotech and large pharmaceutical clients from facilities in Tustin and Costa Mesa, California.
Ownership category
akta.pro rank

Avid Bioservices industry classification

Industry
Product category
Biologics Contract Manufacturing (CDMO)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics contract manufacturing
  • Mammalian cell culture
  • Biopharmaceutical CDMO services
  • CGMP manufacturing
  • Process development services

Where Avid Bioservices is headquartered

Location

Headquarters

HQ city
Tustin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Avid Bioservices business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Avid generates revenue through fee-for-service contract manufacturing agreements for mammalian cell culture biologics. Services span process development, analytical testing, CGMP manufacturing, and tech transfer. Revenue is project-based with long-term client relationships typically encompassing multiple phases from early development through commercial supply.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels10 records

Avid Bioservices product offering

Product offering

Core offering

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end mammalian cell-culture manufacturing services for biopharmaceutical clients. Its offerings span process development, analytical services, CGMP clinical and commercial manufacturing, and quality systems, delivered through two specialized California facilities—a 160,000 sq. ft. Tustin campus for late-stage/commercial production and a 78,000 sq. ft. Costa Mesa Early Phase Center of Excellence.

Product overview

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing mammalian cell-culture manufacturing services. The company offers a unified portfolio centered on Mammalian Protein Development & Manufacturing as its core product, supplemented by two specialized facilities: the Early Phase Center of Excellence in Costa Mesa (78,000 sq. ft.) for early clinical programs and the Clinical & Commercial Manufacturing campus in Tustin (160,000 sq. ft.) for late-stage and commercial production. The service portfolio encompasses four integrated modules—Process Development, CGMP Manufacturing, Analytical Services, and Quality Systems—that collectively enable end-to-end capabilities from concept to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mammalian Protein Development & Manufacturing End-to-end CDMO services for mammalian protein production spanning early development through commercial CGMP manufacturing, including process development, analytical services, and quality systems for biotech and pharmaceutical clients.
  • Early Phase Center of Excellence 78,000 square foot purpose-built facility in Costa Mesa, California designed to support early clinical programs with integrated cell line development, process development, analytical development, IND-enabling activities, and early formulation development.
  • Clinical & Commercial Manufacturing (Tustin Campus) Approximately 160,000 sq. ft. integrated mammalian protein process development and CGMP manufacturing facility supporting late-stage clinical and commercial biologics production with over 20,000L of installed single-use bioreactor capacity.

Quantifiable outcome

  • 10 successful pre-approval/pre-license inspections
  • +3 more outcomes

Companies that use Avid Bioservices

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Avid Bioservices technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Avid Bioservices partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CHO PluscoreStrategic or Co-development Partner · 5 August 2025CHO Plus partnered with Avid Bioservices as scale-up partner for BARDA's BioMaP Consortium project developing high productivity CHO cell lines for filovirus monoclonal antibody production. Avid provides manufacturing scale-up services to support industrial-scale requirements for the BARDA-funded program worth up to $10.4 million over 30 months.
  • BARDA BioMaP ConsortiumcoreOthers · 5 August 2025Avid Bioservices serves as scale-up partner within BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), supporting domestic manufacturing capacity for medical countermeasures including filovirus monoclonal antibodies.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Avid Bioservices competitors and assessment

Company assessment

Broad incumbents

  • Samsung Biologics: Samsung Biologics is one of the world's largest mammalian cell culture CDMOs with massive bioreactor capacity (600,000L+). Direct competitor for commercial-scale biologics manufacturing contracts but operates at materially larger scale than Avid.
  • Lonza Biologics: Lonza's Biologics division is the global #1 CDMO offering mammalian cell culture manufacturing from early development through commercial supply. Closest direct competitor in scale, scope, and service mix; competes with Avid for both early-phase and commercial programs.
  • Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth Biotechnologies is a leading global CDMO offering mammalian and microbial biologics manufacturing. Notably, Avid's new CEO Kenneth Bilenberg was previously COO of Fujifilm Biotechnologies, making this a particularly relevant peer relationship.
  • WuXi Biologics: WuXi Biologics is a major global biologics CDMO based in China offering end-to-end mammalian cell culture services. A key direct competitor but increasingly losing US biotech work to Avid and other US-based CDMOs due to BIOSECURE Act and onshoring trends.
  • Catalent (Novo Holdings): Catalent is a major global CDMO (now under Novo Holdings) with biologics manufacturing capabilities among other modalities. Overlaps with Avid in mammalian biologics but operates across a much broader service portfolio.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher's Pharma Services (including the legacy Patheon and Brammer Bio biologics operations) is a major global CDMO offering mammalian biologics manufacturing. Broad incumbent competing for late-stage and commercial programs at scale.

Direct peers

  • AGC Biologics: AGC Biologics is a pure-play mammalian and microbial biologics CDMO with comparable scale to Avid (~20,000L range). Direct competitor for mid-market biotech and pharma biologics manufacturing programs.
  • Rentschler Biopharma: Rentschler Biopharma is a privately held, Germany-based CDMO specializing in mammalian cell culture biologics manufacturing. Very comparable in scale, service mix, and target market (mid-market biotech) to Avid.
  • KBI Biopharma: KBI Biopharma is a US-based CDMO focused on mammalian cell culture biologics development and manufacturing. Direct competitor particularly for early-phase programs; comparable footprint and customer profile.

Emerging players

  • Bionova Scientific: Bionova Scientific is a US-based biologics CDMO focused on mammalian cell culture development and GMP manufacturing for early-phase programs. Emerging peer with similar focus area to Avid's Early Phase Center of Excellence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Avid Bioservices social profiles

Digital presence

Avid Bioservices compliance and trust

Trust signal

Compliance5 records

Avid Bioservices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avid Bioservices leadership team

Management profile

Number of profiles

Profiles9 records

Avid Bioservices funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avid Bioservices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avid Bioservices

What does Avid Bioservices do?

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end mammalian cell-culture manufacturing services for biopharmaceutical clients. Its offerings span process development, analytical services, CGMP clinical and commercial manufacturing, and quality systems, delivered through two specialized California facilities—a 160,000 sq. ft. Tustin campus for late-stage/commercial production and a 78,000 sq. ft. Costa Mesa Early Phase Center of Excellence.

Is Avid Bioservices a public or private company?

Avid Bioservices is a private company. It is classified as private equity controlled and is currently operating.

When was Avid Bioservices founded?

Avid Bioservices was founded in 1993. It employs 251 to 500 people.

Where is Avid Bioservices based?

Avid Bioservices is headquartered in Tustin, United States, in the North America region.

How does Avid Bioservices make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Avid Bioservices's main competitors?

Broad incumbents on record are Samsung Biologics, Lonza Biologics, Fujifilm Diosynth Biotechnologies, WuXi Biologics, Catalent (Novo Holdings) and Thermo Fisher Scientific (Patheon). Direct peers are AGC Biologics, Rentschler Biopharma and KBI Biopharma. Bionova Scientific is listed as an emerging player.

Does Avid Bioservices have an API?

No public API is recorded for Avid Bioservices.

What industry is Avid Bioservices in?

Avid Bioservices's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsDownstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules MisbehaveA webinar will feature panelists from AstraZeneca, Avid Bioservices, and Thermo Fisher discussing downstream purification strategies for complex antibody therapeutics that deviate from standard platform assumptions. The discussion covers alternative affinity approaches, polishing with IEX, HIC, and mixed-mode chromatography, and balancing speed, yield, purity, cost, and regulatory expectations.PR NewswireCity of Tustin Honors Avid Bioservices, the Reshoring LeaderAvid Bioservices received the City of Tustin's Business Recognition Award in the Industrial & Manufacturing – Life Sciences category. CEO Kenneth Bilenberg said the U.S. needs more mid-scale biologics capacity, and Mayor Austin Lumbard noted Avid's 30-year presence. The company is developing biologics talent with local universities.BioProcess InternationalPE set to buy CDMO Avid Bioservices for $1.1 billionPrivate equity firms GHO and Ampersand have agreed to acquire CDMO Avid Bioservices for $1.1 billion, representing a 22% premium on the stock price. The transaction is expected to close in the first quarter of 2025 and expands both firms' portfolios in the life sciences outsourcing sector. Avid operates biologics facilities in California that have undergone recent capacity expansions.PR NewswireAvid Bioservices nomme Maria Ebro Andreasen au poste de Chief People Officer pour soutenir la croissance continue et la stratégie des talentsAvid Bioservices, a leading CDMO for biological products headquartered in Tustin, California, announced the appointment of Maria Ebro Andreasen as Chief People Officer on May 19, 2026. In this role, Maria will lead the company's HR strategy, focusing on recruitment and onboarding, university partnerships, skills development, and employee retention to support Avid's continued growth. The company is simultaneously expanding its talent pipeline through strengthened university partnerships and internship programs in Southern California.PR NewswireAvid Bioservices ernennt Maria Ebro Andreasen zur Personalchefin, um das weitere Wachstum und die Talentstrategie voranzutreibenAvid Bioservices appointed Maria Ebro Andreasen as its HR head to drive growth and talent strategy. The company will expand its team, university partnerships, and internship programs to secure a pipeline of biologic production talent. The appointment aims to support Avid's expansion to meet rising customer demand.Pulse 2.0Avid Bioservices: Maria Ebro Andreasen Appointed Chief People Officer To Support Growth And Talent StrategyAvid Bioservices appointed Maria Ebro Andreasen as Chief People Officer as the biologics CDMO continues expanding its operations and workforce to meet increasing customer demand. Andreasen will oversee the company's human resources strategy, including recruitment, retention, university partnerships, and internship initiatives aimed at building a sustainable talent pipeline. The company is increasing investments in training programs across Southern California to support its growth strategy while preserving its culture.citybizAvid Bioservices Adds Maria Ebro Andreasen as Chief People OfficerAvid Bioservices has appointed Maria Ebro Andreasen as chief people officer as the Tustin, California-based contract biologics manufacturer expands its workforce to meet growing demand from biotech and pharmaceutical customers. Andreasen will lead HR strategy including recruitment, onboarding, employee development, and university partnerships aimed at addressing talent shortages in the biologics manufacturing sector. The appointment reflects broader workforce pressures as CDMOs compete for specialized talent in bioprocessing, quality systems, and regulatory operations.AijournAvid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent StrategyAvid Bioservices announced the appointment of Maria Ebro Andreasen as Chief People Officer to lead the company's human resources strategy. The appointment supports Avid's ongoing scaling efforts to meet increasing customer demand, including expansion of recruitment, university partnerships, and internship programs across Southern California. The company stated this move is part of its broader commitment to building a talent pipeline for the biologics manufacturing workforce while maintaining its culture and expertise.PR NewswireAvid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent StrategyAvid Bioservices, a biologics CDMO headquartered in Tustin, California, has appointed Maria Ebro Andreasen as Chief People Officer to lead the company's human resources strategy amid plans to scale operations and meet growing customer demand. The company is simultaneously expanding its workforce and deepening partnerships with universities and internship programs across Southern California to build a talent pipeline for the biologics manufacturing sector. The appointment underscores Avid's strategy to grow intentionally while preserving its culture and expertise as it aims to help more patients with both novel drugs and approved medicine supply.PR NewswireAvid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent StrategyAvid Bioservices announced the appointment of Maria Ebro Andreasen as Chief People Officer to support the company's continued growth and scaling of operations in the biologics CDMO sector. The company is simultaneously expanding its workforce, university partnerships, and internship programs in Southern California to build a long-term talent pipeline. As a contract development and manufacturing organization, Avid aims to support increasing customer demand while maintaining operational quality and company culture.